The Penicillin and Streptomycin dosage market in Estonia has experienced a significant decline from 2013 to 2023, starting at 6.9874 million USD and reaching 2.3008 million USD. The market suffered substantial year-on-year declines in most years, notably a nearly 17.73% drop from 2022 to 2023. The compound annual growth rate over the last five years was -11.1%, indicating a persistent downward trend.
Future trends to watch for:
- Potential market stabilization or further decline due to changing healthcare practices and antibiotic usage regulations.
- Influence of new antibiotics and alternative treatment options gaining popularity.
- Impact of global pharmaceutical market trends and regional healthcare policies on Estonia's market.
| # | 33 Countries | US Dollars | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 United States | 4,303,400,000 | 2023 | +0.61% | +1.48% | View data |
| 2 | 2 United Kingdom | 730,000,000 | 2023 | -1.31% | -1.45% | View data |
| 3 | 3 France | 717,200,000 | 2023 | -1.91% | +0.034% | View data |
| 4 | 4 Italy | 622,330,000 | 2023 | -3.96% | -4.86% | View data |
| 5 | 5 Germany | 476,270,000 | 2023 | +1.03% | +1.1% | View data |
| 31 | 31 Armenia | 5,084,600 | 2023 | -2.21% | -0.94% | View data |
| 32 | 32 Luxembourg | 3,435,800 | 2023 | +0.84% | +2.7% | View data |
| 33 | 33 Estonia | 2,300,800 | 2023 | -17.73% | -11.1% | |
